For the quarter ending 2025-09-30, CVSI had -$505K decrease in cash & cash equivalents over the period. -$317K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of property and equipment | 11 | 89 |
| Acquisition of business, net of cash acquired | 0 | 0 |
| Net cash flows used in investing activities | -11 | -89 |
| Proceeds from note payable | 0 | 1,200 |
| Debt issuance costs related to note payable | 0 | 82 |
| Repayment of note payable | 214 | 686 |
| Repayment of unsecured debt | 20 | 119 |
| Net cash flows provided by financing activities | -234 | 313 |
| Effect of exchange rate changes on cash | -1 | 2 |
| Depreciation and amortization | 31 | 140 |
| Stock-based compensation | 124 | 250 |
| Amortization of debt discount | 107 | 279 |
| Amortization of right of use assets | 63 | 112 |
| Gain in fair value of contingent consideration liabilities | 0 | - |
| Other | 23 | 105 |
| Accounts receivable, net | -142 | 12 |
| Inventory | -132 | -698 |
| Prepaid expenses and other | -64 | -77 |
| Accounts payable and accrued expenses | -563 | -513 |
| Benefit from reversal of accrued payroll tax (note 12) | 0 | -522 |
| Gain on debt extinguishment | 0 | 38 |
| Product sales, net | 3,256 | - |
| Cost of goods sold | 1,677 | - |
| Gross profit | 1,579 | - |
| Research and development expense | 24 | - |
| Sales expense | 691 | - |
| Marketing expense | 429 | - |
| General and administrative expense | 710 | - |
| Benefit from reversal of accrued payroll taxes | 0 | - |
| Total operating expenses | 1,854 | - |
| Operating loss | -275 | - |
| Gain on extinguishment of debt | 0 | - |
| Other expense, net | -107 | - |
| Loss before income taxes | -382 | - |
| Income tax expense | 0 | - |
| Net loss | -382 | -370 |
| Net cash flows used in operating activities | -306 | 206 |
| Net decrease in cash | -505 | 432 |
| Cash and cash equivalents at beginning of period | 454 | - |
| Cash and cash equivalents at end of period | 381 | - |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)